Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathalie Labarriere

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Oncoimmunology|January 4, 2018
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Sylvain Simon, Nathalie Labarriere
Immunotherapy|April 6, 2011
Is antigen specificity the key to efficient adoptive T-cell therapy?Nathalie Labarriere, Amir Khammari, Francois Lang, et al.
Immunotherapy|January 18, 2018
Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, FranceSylvain Simon, Maud Charpentier, Ignacio Anegon, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2010
A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccinationAnne Rogel, Virginie Vignard, Mathilde Bobinet, et al.
Bulletin Du Cancer|September 6, 2003
[Passive immunotherapy of melanoma]Francine Jotereau, Nathalie Labarriere, Nadine Gervois, et al.
Plos One|October 3, 2013
Overexpression of meloe gene in melanomas is controlled both by specific transcription factors and hypomethylationMathilde Bobinet, Virginie Vignard, Laetitia Florenceau, et al.
Plos One|January 4, 2013
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patientsMathilde Bobinet, Virginie Vignard, Anne Rogel, et al.
Cancer Immunology, Immunotherapy : CII|July 10, 2008
A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patientsYann Godet, Annabelle Bonnin, Yannik Guilloux, et al.
The Journal of Experimental Medicine|October 22, 2008
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiencyYann Godet, Agnès Moreau-Aubry, Yannik Guilloux, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2009
An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 contextYann Godet, Agnès Moreau-Aubry, Dimitri Mompelat, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Oncoimmunology|January 4, 2018
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Sylvain Simon, Nathalie Labarriere
Immunotherapy|April 6, 2011
Is antigen specificity the key to efficient adoptive T-cell therapy?Nathalie Labarriere, Amir Khammari, Francois Lang, et al.
Immunotherapy|January 18, 2018
Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, FranceSylvain Simon, Maud Charpentier, Ignacio Anegon, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2010
A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccinationAnne Rogel, Virginie Vignard, Mathilde Bobinet, et al.
Bulletin Du Cancer|September 6, 2003
[Passive immunotherapy of melanoma]Francine Jotereau, Nathalie Labarriere, Nadine Gervois, et al.
Plos One|October 3, 2013
Overexpression of meloe gene in melanomas is controlled both by specific transcription factors and hypomethylationMathilde Bobinet, Virginie Vignard, Laetitia Florenceau, et al.
Plos One|January 4, 2013
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patientsMathilde Bobinet, Virginie Vignard, Anne Rogel, et al.
Cancer Immunology, Immunotherapy : CII|July 10, 2008
A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patientsYann Godet, Annabelle Bonnin, Yannik Guilloux, et al.
The Journal of Experimental Medicine|October 22, 2008
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiencyYann Godet, Agnès Moreau-Aubry, Yannik Guilloux, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2009
An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 contextYann Godet, Agnès Moreau-Aubry, Dimitri Mompelat, et al.
Pageof 2